Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is conducting a study titled ‘Patient-Reported Outcomes Associated With COVID-19 and Influenza: A Prospective Survey Study on Outpatient Symptomatic Adults With Test-Confirmed Illness in the United States.’ The study aims to understand the symptoms and health outcomes of individuals with COVID-19 or influenza, and the effects of COVID-19 vaccines on those with COVID-19. This research is significant as it provides insights into the real-world impact of these illnesses and vaccines.
The study tests the Pfizer BioNTech COVID-19 vaccine, a biological intervention aimed at preventing COVID-19. Participants are adults with test-confirmed COVID-19 or influenza and at least one symptom, with data collected through surveys over six months.
This is an observational, prospective cohort study. Participants are grouped into COVID-19 positive and influenza positive cohorts, with no masking involved. The primary purpose is to gather data on patient-reported outcomes over time.
The study started on January 31, 2022, with primary completion and estimated completion dates yet to be announced. The last update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and anticipating results.
The study’s findings could influence Pfizer’s stock performance by providing valuable data on vaccine efficacy and illness impact, potentially affecting investor sentiment. In the broader industry context, this study might impact competitors by setting benchmarks for vaccine effectiveness and patient outcomes.
The study is currently recruiting, with further details available on the ClinicalTrials portal.